Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$4.01 USD
-0.15 (-3.61%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $3.98 -0.03 (-0.75%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
Monte Rosa Therapeutics, Inc. [GLUE]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MRT-6160 Preclinical Data at DDW; Layering in Recent Offering
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; MRT-2359 RP2D in Q2:24, MRT-6160 Ph1 Data in Q1:25
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Stay Glued for MRT-2359 Updates Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM and $11 PT: The QuEEN of Monte Rosa
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Learnings From FASEB?s Ubiquitin Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
|